Plus Therapeutics Inc (NASDAQ: PSTV) on Tuesday, plunged -0.10% from the previous trading day, before settling in for the closing price of $0.31. Within the past 52 weeks, PSTV’s price has moved between $0.24 and $2.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -3.61% annually for the last half of the decade. The company achieved an average annual earnings per share of 62.82%. With a float of $29.81 million, this company’s outstanding shares have now reached $32.72 million.
In an organization with 21 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -116.81%, operating margin of -1167.47%, and the pretax margin is -2120.25%.
Plus Therapeutics Inc (PSTV) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Plus Therapeutics Inc is 8.87%, while institutional ownership is 4.89%. The most recent insider transaction that took place on May 15 ’25, was worth 20,276. Before that another transaction happened on Sep 13 ’24, when Company’s Director bought 4,000 for $1.50, making the entire transaction worth $5,996. This insider now owns 15,188 shares in total.
Plus Therapeutics Inc (PSTV) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.23 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 62.82% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 49.89% during the next five years compared to 46.51% growth over the previous five years of trading.
Plus Therapeutics Inc (NASDAQ: PSTV) Trading Performance Indicators
Plus Therapeutics Inc (PSTV) is currently performing well based on its current performance indicators. A quick ratio of 0.99 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.50, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.67 in one year’s time.
Technical Analysis of Plus Therapeutics Inc (PSTV)
Let’s dig in a bit further. During the last 5-days, its volume was 2.78 million. That was inferior than the volume of 11.7 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 8.99%. Additionally, its Average True Range was 0.07.
During the past 100 days, Plus Therapeutics Inc’s (PSTV) raw stochastic average was set at 3.31%, which indicates a significant decrease from 10.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 135.96% in the past 14 days, which was lower than the 352.82% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5371, while its 200-day Moving Average is $1.0610. However, in the short run, Plus Therapeutics Inc’s stock first resistance to watch stands at $0.3122. Second resistance stands at $0.3157. The third major resistance level sits at $0.3215. If the price goes on to break the first support level at $0.3029, it is likely to go to the next support level at $0.2971. The third support level lies at $0.2936 if the price breaches the second support level.
Plus Therapeutics Inc (NASDAQ: PSTV) Key Stats
Market capitalization of the company is 10.10 million based on 17,000K outstanding shares. Right now, sales total 5,820 K and income totals -12,980 K. The company made 1,060 K in profit during its latest quarter, and -17,400 K in sales during its previous quarter.
